drugset
drugset / Trial / NCT04250207

Study to Investigate the Safety and Efficacy of K-321 in Patients With Fuchs Endothelial Corneal Dystrophy (FECD) Following Descemetorhexis

NCT04250207 ↗

Phase 2 Completed 65 enrolled Kowa Research Institute, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this study is to investigate the effect of K-321 in patients with Fuchs endothelial corneal dystrophy (FECD) after descemetorhexis.

Timeline

Start
2020-06-23
Primary completion
2021-09-22
Completion
2022-06-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Ripasudil Small molecule — Topical

Indications

Fuchs' endothelial dystrophy